☆ 4.4 Article

Structure basis of two nanobodies neutralizing SARS-CoV-2 Omicron variant by targeting ultra-conservative epitopes

JOURNAL OF STRUCTURAL BIOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Nanoscience & Nanotechnology

A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529)

Yuying Lu et al.

Summary: Nanobodies screened from high-throughput libraries have shown potential as candidates for developing preventive and therapeutic antibodies. In particular, the multivalent nanobody LS-B-B2 demonstrated superior neutralizing activity against the Omicron (B.1.1.529) variant.

INTERNATIONAL JOURNAL OF NANOMEDICINE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Development of a highly specific and sensitive VHH-based sandwich immunoassay for the detection of the SARS-CoV-2 nucleoprotein

Marion Gransagne et al.

Summary: This study developed a sandwich immunoassay to specifically detect the nucleoprotein (N) of SARS-CoV-2. Seven antibodies were identified that recognized the full N protein and did not cross react with nucleoproteins from common human coronaviruses. The antibodies mainly targeted conformational epitopes in the C-terminal or N-terminal domains and were able to detect SARS-CoV-2 variants.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

The role of single-domain antibodies (or nanobodies) in SARS-CoV-2 neutralization

Arghavan Zebardast et al.

Summary: Nanobodies, with high affinity to neutralize SARS-CoV-2, are a new class of recombinant antibodies that may serve as an effective and cost-efficient treatment for COVID-19.

MOLECULAR BIOLOGY REPORTS (2022)

Add to Collection

Article Multidisciplinary Sciences

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Delphine Planas et al.

Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift

Elisabetta Cameroni et al.

Summary: The Omicron variant of SARS-CoV-2 has raised concerns due to its 37 amino acid substitutions in the spike protein, particularly in the receptor-binding domain (RBD), leading to increased binding affinity with human ACE2. Neutralizing activity against Omicron was greatly reduced in convalescent and vaccinated individuals compared to the ancestral virus, but this decrease was less significant after a third vaccine dose. Broadly neutralizing monoclonal antibodies recognizing conserved RBD epitopes may be crucial in combating the Omicron variant and future zoonotic transmissions.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Yunlong Cao et al.

Summary: The Omicron variant of SARS-CoV-2 contains 15 mutations in the receptor-binding domain, leading to evasion of over 85% of tested neutralizing antibodies. Different epitope groups of neutralizing antibodies are affected to varying degrees by single mutations of Omicron. Antibodies targeting the conserved region of sarbecovirus remain most effective against Omicron.

NATURE (2022)

Add to Collection

Review Cell Biology

Mechanisms of SARS-CoV-2 entry into cells

Cody B. Jackson et al.

Summary: The entry of SARS-CoV-2 into host cells is facilitated by the interaction between the viral spike protein and ACE2, leading to virus-cell membrane fusion, which has been extensively studied at the structural and cellular levels worldwide. This understanding has paved the way for the development of effective vaccines in response to the COVID-19 pandemic, caused by the infection with SARS-CoV-2.

NATURE REVIEWS MOLECULAR CELL BIOLOGY (2022)

Add to Collection

Review Immunology

SARS-CoV-2: Recent Variants and Clinical Efficacy of Antibody-Based Therapy

Desh Deepak Singh et al.

Summary: Multiple variants of SARS-CoV-2, including B.1.1.7, B1.351, P.1, B.1.617.2 variants, and B.1.1.529, have emerged and are prevalent globally. These variants possess mutations in the spike protein, resulting in increased transmissibility and pathogenicity. Urgent measures are needed to address these variants of concern (VOCs). Antibody-based treatments targeting the spike protein have shown promising results in combating SARS-CoV-2. However, further clinical evaluation is still required to verify their efficacy and ensure independent effectiveness.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

SARS-CoV-2 Mutations and their Viral Variants

Begum Cosar et al.

Summary: Mutations in SARS-CoV-2 are occurring spontaneously and new variants are emerging. Understanding the mutations and their frequencies is crucial for the development of drug combinations and clinical applications. Research on effective therapeutic and preventive strategies is needed due to the lack of current options.

CYTOKINE & GROWTH FACTOR REVIEWS (2022)

Add to Collection

Article Multidisciplinary Sciences

An extended conformation of SARS-CoV-2 main protease reveals allosteric targets

Zengchao Sun et al.

Summary: This study reveals the structure and function of the coronavirus M-proteinase, showing that it forms an active state through a folding process, providing a new approach for developing antiviral drugs against coronaviruses.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Structural basis of nanobodies neutralizing SARS-CoV-2 variants

Zhenzhong Shi et al.

Summary: This study identified high-affinity nanobodies from camels immunized with the receptor-binding domain (RBD) of SARS-CoV-2 spike protein and demonstrated their ability to target the virus and inhibit viral escape. These findings contribute to the development of antibodies against future variants of SARS-CoV-2 and are important for combating coronavirus epidemics and pandemics.

STRUCTURE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants

Xiaojing Chi et al.

Summary: Researchers have developed a biparatopic antibody with ultrapotent and broad-spectrum neutralization activity against multiple SARS-CoV-2 variants, including the new Omicron variant. The antibody has the potential for clinical applications.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Add to Collection

Article Multidisciplinary Sciences

Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape

Paul-Albert Koenig et al.

Summary: In this study, new neutralizing nanobodies targeting the SARS-CoV-2 spike protein were developed, showing enhanced neutralizing activity through engineering technology and successfully suppressing the emergence of escape mutants. The findings suggest that nanobodies can neutralize through receptor binding competition and also render virions noninfectious.

SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Wanwisa Dejnirattisai et al.

Summary: Antibodies play a crucial role in immune protection against SARS-CoV-2, with some being used as therapeutics. A study identified 377 human monoclonal antibodies, focusing on 80 that bind the virus spike, and found that most highly inhibitory antibodies can block the virus-receptor interaction. Novel binding modes of potent inhibitory antibodies were discovered, showing potential for prophylactic or therapeutic use in animal models.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Emma C. Thomson et al.

Summary: SARS-CoV-2 virus can mutate and evade immunity, with mutations like N439K conferring resistance against neutralizing monoclonal antibodies and enhancing binding affinity to hACE2 receptor. Despite similar in vitro replication fitness and clinical outcomes compared to wild type, N439K mutation highlights the importance of ongoing molecular surveillance for guiding vaccine and therapeutic development and usage.

CELL (2021)

Add to Collection

Article Cell Biology

A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration

Xilin Wu et al.

Summary: Neutralizing nanobodies derived from an alpaca immunized with SARS-CoV-2 spike glycoprotein show potential therapeutic effects against COVID-19. A trimer of Nbs, Nb-15-NbH-Nb-15, exhibits high neutralization potency against SARS-CoV-2 live virus and variants with a long half-life. Intranasal administration of Nb-15-Nb-H-Nb-15 provides effective protection against SARS-CoV-2 infection in transgenic hACE2 mice for both prophylactic and therapeutic purposes.

CELL REPORTS (2021)

Add to Collection

Article Multidisciplinary Sciences

Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants

Jianliang Xu et al.

Summary: The study found that camelid nanobodies can effectively circumvent vaccine escape caused by mutations in the novel coronavirus. These nanobodies are able to neutralize SARS-CoV-2 variants through two mechanisms, demonstrating promising potential in preventing COVID-19 mortality when vaccines are compromised.

NATURE (2021)

Add to Collection

Review Immunology

Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity

Hylemariam Mihiretie Mengist et al.

Summary: COVID-19, caused by SARS-CoV-2, has resulted in over 4.9 million deaths and is having devastating effects on the global healthcare system. Understanding the impact of viral mutations on vaccines and immunity is crucial for designing effective strategies to combat emerging variants.

SEMINARS IN IMMUNOLOGY (2021)

Add to Collection

Review Immunology

SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene

Hyunjhung Jhun et al.

Summary: As of September 21, 2021, over 228 million cases of COVID-19 have been reported worldwide, resulting in over 4 million deaths. The predominant circulating variants of concern are alpha, beta, gamma, and delta, originating from different countries like the UK, South Africa, Brazil/Japan, and India, respectively. These variants exhibit unique mutations in the spike gene, which may impact their infectivity and pathogenicity.

IMMUNE NETWORK (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Nanobodies to study protein conformational states

Tomasz Uchanski et al.

CURRENT OPINION IN STRUCTURAL BIOLOGY (2020)

Add to Collection

Article Virology

Transmission dynamics and evolutionary history of 2019-nCoV

Xingguang Li et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Cell entry mechanisms of SARS-CoV-2

Jian Shang et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Markus Hoffmann et al.

MOLECULAR CELL (2020)

Add to Collection

Article Microbiology

Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike

Jiandong Huo et al.

CELL HOST & MICROBE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Luca Piccoli et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

Daming Zhou et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Christopher O. Barnes et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges

Beata Turonova et al.

SCIENCE (2020)

Add to Collection

Review Immunology

The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development

Sana O. Alturki et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

Hejun Liu et al.

IMMUNITY (2020)

Add to Collection

Article Multidisciplinary Sciences

An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

Michael Schoof et al.

SCIENCE (2020)

Add to Collection

Review Medicine, Research & Experimental

Structure and development of single domain antibodies as modules for therapeutics and diagnostics

Robert J. Hoey et al.

EXPERIMENTAL BIOLOGY AND MEDICINE (2019)

Add to Collection

Review Biochemistry & Molecular Biology

Nanobodies: Natural Single-Domain Antibodies

Serge Muyldermans

ANNUAL REVIEW OF BIOCHEMISTRY, VOL 82 (2013)

Add to Collection

Article Biochemical Research Methods

MolProbity: all-atom structure validation for macromolecular crystallography

Vincent B. Chen et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2010)

Add to Collection

Article Biochemical Research Methods

Coot:: model-building tools for molecular graphics

P Emsley et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2004)

Add to Collection

Article Biochemical Research Methods

PHENIX:: building new software for automated crystallographic structure determination

PD Adams et al.

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.